Deciphering Disease Heterogeneity, Optimizing Dosing Regimens & De-Risking Emerging Targets to Transform Long-Term QoL & Address Unmet Needs Across Rare & Common Inflammatory Skin Disease
The dermatology market is entering a pivotal new era. As competition intensifies across Atopic Dermatitis and Psoriasis, developers are under growing pressure to demonstrate meaningful differentiation, accelerate development timelines and identify the next generation of high-value opportunities beyond today's established targets and therapies.
The 10th Dermatology Drug Development Summit is the industry's premier forum dedicated to advancing the discovery, development and commercialization of innovative therapies for inflammatory skin disease. Bringing together 90+ leaders spanning discovery, translational medicine, preclinical development, clinical strategy, medical affairs and commercial functions, the meeting provides a unique opportunity to benchmark emerging science, evaluate novel targets and share practical lessons from across the dermatology pipeline.
This year's expanded program explores the future of dermatology innovation across Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Acne, Epidermolysis Bullosa, Prurigo Nodularis and more. With dedicated Discovery & Preclinical and Clinical & Commercial tracks, attendees will gain actionable insights into AI-enabled target discovery, translational de-risking, biomarker development, next-generation modalities, dosing optimization, clinical differentiation and commercialization strategy.
Join the companies shaping the future of dermatology to discover where the next breakthrough therapies, and the next major market opportunities, will emerge.
The small size enabled greater intimacy, with more networking opportunities and interactive Q&A during the presentations compared to larger conferences.
Chief Executive & Scientific Officer, Alnivo Therapeutics
Extremely intimate group of experts so very easy to network and make connections. Very focused topics
Preclinical Manager, Aquestive Therapeutics
Good size, so plenty of opportunities to talk with speakers and other participants. Good mix of early and later stage therapeutics.
Head of Translational Medicine, Engimmune Therapeutics
Explore the Full Agenda
- Explore 35+ sessions covering discovery, translational medicine, clinical development, commercialization and investment strategy
- See how leaders from AbbVie, Galderma, Eli Lilly, Merck, Rubedo, AOBiome and more are advancing next-generation dermatology pipelines
- Discover emerging opportunities across Atopic Dermatitis, Psoriasis, HS, Vitiligo, Alopecia Areata, Acne, EB and other high-growth dermatology indications
- Preview the dedicated Discovery & Preclinical and Clinical & Commercial tracks designed to accelerate learning and networking
- Benchmark your strategy against the latest thinking on AI-driven discovery, novel targets, biomarker development, dosing optimization and market differentiation
Our Expert Speaker Faculty:
2026 Partners:
Other Events in the Series
Explore the Agenda to Discover the Translational to Access Priorities Shaping Dermatology R&D in 2026
Explore a focused agenda of scientific case studies, expert panels and interactive discussions designed to help you discover novel targets, improve translational confidence, optimize clinical development, differentiate therapies and accelerate the next generation of dermatology innovation across both common and rare inflammatory skin diseases.
Partner to Position Your Solutions at the Centre of Active Dermatology Pipelines
Partner with the summit to showcase your capabilities to senior pharma and biotech teams actively seeking support across biomarkers, imaging, clinical trials, manufacturing and formulation.
Join Biopharma Experts to Connect with the Decision-Makers Driving Dermatology Development Forward
Join a global audience of 90+ senior leaders from pharma and biotech for high-value networking, candid peer exchange and relationship-building across preclinical and late-stage development, access and launch.